14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ROIV vs SYRE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Roivant Sciences Ltd. Common Shares (ROIV) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). ROIV carries a Unified Composite Score of 39.6/100 (SELL) at $38.77 (N/M Forward P/E, -3226.3% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While SYRE currently prints a higher short-term Unified Composite Score (44.4/100 HOLD vs. ROIV 39.6/100 SELL), ROIV captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-3226.3% vs. 0.0% operating margin) and revenue trajectory (+2135.6% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ROIV vs SYRE. Trailing 12-month operating profitability (ROIV -3226.3% vs SYRE 0.0%) and valuation multiples (ROIV N/M vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ROIV vs SYRE Key Questions & Quantitative Answers
As of Nov 16, 2026, Roivant Sciences Ltd. Common Shares (ROIV) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). ROIV carries a Unified Composite Score of 39.6/100 (SELL) at $38.77 (N/M Forward P/E, -3226.3% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SYRE currently prints a higher short-term Unified Composite Score (44.4/100 HOLD vs. ROIV 39.6/100 SELL), ROIV captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-3226.3% vs. 0.0% operating margin) and revenue trajectory (+2135.6% vs. +0.0% YoY).
ROIV leads the Growth & Scale pillar: ROIV posts +2135.6% YoY revenue growth and -96.1% YoY earnings growth on $41M TTM revenue (N/A gross margin, -3226.3% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ROIV generates $41M in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, ROIV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.
ROIV and SYRE trade at balanced relative valuation multiples. ROIV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-81.2% FCF margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ROIV (-8.5% ROE) versus SYRE (-35.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ROIV carries 48.1% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 49% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.